Key facts
- It has raised $30.2M; the latest was Later Stage VC in Jul 2025.
- Notable investors include GL Ventures, YuanBio Venture Capital, Yonghua Capital, Furong Capital, Zhuhai Gree Financial Investment — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Pushkang
- ·The full record, as it builds
Funding rounds
No funding rounds for Pushkang are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pushkang
Developer of microfluid analysis biotechnology designed for the chronic disease management detection field. The company focuses on in vitro diagnostic (IVD) reagents and clinical laboratory analysis instruments, enabling biomedical researchers to better analyse fluid samples.
- Sector
- Healthcare
- HQ
- Shaoxing, China
- Founded
- 2014
- Employees
- 300
- Website
- pushkang.com.cn/
- Ownership
- Privately Held (backing)
Pushkang doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pushkang shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pushkang in its N-PORT filings yet. We sweep new filings monthly.